Form 8-K - Current report:
SEC Accession No. 0001829126-26-000110
Filing Date
2026-01-08
Accepted
2026-01-08 16:07:25
Documents
16
Period of Report
2026-01-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalabio_8k.htm   iXBRL 8-K 33845
2 EXHIBIT 1.1 kalabio_ex1-1.htm EX-1.1 245344
3 EXHIBIT 5.1 kalabio_ex5-1.htm EX-5.1 16104
4 GRAPHIC ex5-1_001.jpg GRAPHIC 4382
5 GRAPHIC ex5-1_002.jpg GRAPHIC 1953
  Complete submission text file 0001829126-26-000110.txt   526354

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE kala-20260108.xsd EX-101.SCH 2990
7 XBRL LABEL FILE kala-20260108_lab.xml EX-101.LAB 34239
8 XBRL PRESENTATION FILE kala-20260108_pre.xml EX-101.PRE 22342
18 EXTRACTED XBRL INSTANCE DOCUMENT kalabio_8k_htm.xml XML 3091
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 26519667
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)